Published by Josh White on 17th May 2021
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced "promising" new data from its ongoing bexmarilimab 'MATINS' study on Monday, reporting combined headline data from 141 evaluable patients enrolled in the completed first part and the ongoing second part of the study.